| NP_001135835.1 |
Rattus norvegicus |
|
NP_001135835.1 is differentially expressed in 9 experiments [4 up/5 dn]: 2 organism parts: supraoptic nucleus [1 up/0 dn], neurointermediate lobe [0 up/1 dn], 4 compound treatments: diethylstilbestrol [1 up/0 dn], control [0 up/1 dn], ...; 1 clinical treatments, 2 developmental stages |
| Alg3, NP_001135835.1 |
|
ALG3 (Homo sapiens)
Alg3 (Mus musculus)
K09E4.2 (Caenorhabditis elegans)
ALG3 (Saccharomyces cerevisiae)
l(2)not (Drosophila melanogaster)
alg3 (Danio rerio)
(Compare orthologs)
|
|
|
| Glycosyltransferase, ALG3 |
|
|
| endoplasmic reticulum, integral to membrane, transferase activity, transferring hexosyl groups |
|
|
|
Q5M7T0
|
|
|
|
ENSRNOG00000001712
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Diethylstilbestrol
|
Compound treatment |
|
|
Control
|
Compound treatment |
|
|
Supraoptic nucleus
|
Organism part |
|
|
E12.5
|
Developmental stage |
|
|
E16
|
Developmental stage |
|
|
Interleukin 1 beta
|
Compound treatment |
|
|
Neurointermediate lobe
|
Organism part |
|
|
Glucosamine
|
Compound treatment |
|
|
Non-toxic compound
|
Clinical treatment |
|
|
|
|
|
Processing time: 0.123 secs.